跳至主要内容
临床试验/CTRI/2024/02/062998
CTRI/2024/02/062998尚未招募不适用

Long term clinical outcomes and toxicity in cervical cancer patients treated with surgery and chemoRadiation-An institutional observational study.

J prasanthi1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年2月27日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
50
试验地点
1
主要终点
Overall survival

研究概览

简要总结

Worldwide Cervical cancer is the fourth most common cancer among women both in incidence with an estimated 604,000 new cases and deaths with 342,000 cases. In India it accounts for 75,209 new cases with cumulative risk of 1 in 75 females next to breast cancer in which 1 in 29 females will develop cancer. At our hospital around 25% of total patients that we treat will be having cervical cancer. Treatment options for early stage cervical cancer are either surgery or radiation. Overall survival or disease free survival are equal for either treatment. Some selected patients after surgery based on certain pathological risk factors have to receive adjuvant radiation with or without concurrent chemotherapy that results in improved disease outcomes.patients who receive post operative radiation will be having increase in complications. Most of the trials conducted on combined modality treatment are older studies moreover treatment methods also changed over period of time with the advent of newer techniques. The aim of the present study is to report 5 year disease related outcomes and complications in cervical cancer patients treated surgery and radiation at Government College, hospital.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)(—)
性别
Female

入选标准

  • Histopathologically confirmed cervical cancer patients,squamous cell carcinoma or adenocarcinoma, underwent surgery and chemo radiation with curative intent treatment,and having tumors with FIGO stage I or stage II.

排除标准

  • Cervical cancer patients treated with palliative intent.
  • Patients previously treated with either surgery or chemo radiation.
  • Patients treated with radical chemoradiation Patients who are not on regular follow up.

结局指标

主要结局

Overall survival

时间窗: Overall survival is the period from the date of surgery to date of death

次要结局

  • Disease free survival(Disease free survival is the period from the date of surgery to disease recurrence or last follow up.)
  • Toxicity(In this trial we are evaluating late toxicity, which occurs after three months of completion of treatment.)

研究者

发起方
J prasanthi
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr J Prasanthi

Government medical college,hospital,ananthapuramu.

研究点 (1)

Loading locations...

相似试验